1. Introduction {#sec1}
===============

Sjogren\'s syndrome (SS) is a chronic progressive autoimmune disorder characterized by lymphocytic infiltration of the exocrine glands, which affects the salivary and lacrimal glands, presenting dryness of the mouth and eyes. The majority of infiltrating mononuclear cells are CD4+ T cells \[[@B1]\]. Some patients may present diverse extraglandular impairment such as that in the lungs, kidneys, nervous system, and skin affected by this disorder \[[@B2]\]. The predominant serologic findings of pSS are positive anti-nuclear antibodies (ANA), anti-SSA antibodies, and anti-SSB antibodies. Renal involvement is easily ignored by the physicians because the clinical symptoms are often insidious. Growing evidence suggests that patients with pSS may have greater renal injury risk than the general population and the most common renal disease in SS is tubulointerstitial nephritis, responsible for renal tubular acidosis in 20% \[[@B3]\]. However, it is still challenging to diagnose renal involvement in pSS patients.

In the present study, we described the clinical presentation and serologic findings of 840 patients with pSS without renal involvement and 162 patients with renal involvement. We also analyzed whether biochemical markers were useful in identifying renal disease in pSS patients to guide further clinical work.

2. Materials and Methods {#sec2}
========================

2.1. Methods {#sec2.1}
------------

### 2.1.1. Study Population and Clinical Data {#sec2.1.1}

A total of 1002 patients who fulfilled the 2002 classification criteria \[[@B4]\] for pSS from the Rheumatology Department of the Second Affiliated Hospital of Shanxi Medical University between September 2013 and September 2017 were enrolled in this study. The study was approved by the Ethical Committee of the Second Affiliated Hospital of Shanxi Medical University (approval \# 2016KY007). The study design conformed to the current National Health and Family Planning Commission of China ethical standards, with written informed consent provided by all patients.

Sjogren\'s syndrome without other autoimmune diseases is called pSS. pSS patients were diagnosed with clinical data as oral and ocular dryness, constitutional symptoms, vasculitis, and joint, skin, pulmonary, kidney, gastrointestinal tract, and endocrine involvement. The clinical observation items included age, gender, course of disease, glandular symptoms (xerostomia and xerophthalmia), and extraglandular symptoms (arthritis, erythema, edema, and digestive, respiratory, and renal involvement). Routine laboratory examinations were performed including routine blood test, routine urine test, liver function examination, nephric function examination, erythrocyte sedimentation rate (ESR), cystatin C, and *α*~1~-MG. Biochemical tests were performed using standard methods in a Beckman Coulter AU 5800 chemistry analyzer, and serum creatinine measurements were used by an IDMS-traceable method. Immunologic examinations which included anti-SSA, anti-SSB, and rheumatoid factors were performed using an immunoblotting method.

### 2.1.2. Assessment of Renal System Involvement {#sec2.1.2}

We identified those with clinically significant renal involvement.

Clinically significant renal involvement in pSS, either interstitial nephritis or GN, was defined by one or more of the following criteria: Renal tubular acidosis (RTA). Subtypes of RTA were determined as follows \[[@B5]\]: RTA type I (distal): hyperchloremic acidosis with a minimum urine pH ≥ 5.3 and low/normal plasma potassium (\<5.5 mmol/L), based on reduced H+ secretion in the distal tubule; RTA type II (proximal): hyperchloremic acidosis with a minimum urine pH \< 5.3 and low/normal plasma potassium (\<5.5 mmol/L), based on reduced HCO3− reabsorption in the proximal tubule; and RTA type IV: hyperchloremic acidosis with a minimum urine pH \< 5.3 and high plasma potassium (≥5.5 mmol/L), based on reduced H+ and K+ excretion in the distal tubuleKidney biopsy demonstrating histologic features compatible with glomerulonephritis, interstitial nephritis, or bothFanconi syndrome not associated with any known causeElevated serum creatinine levelsProteinuria \> 500 mg/24 hoursActive urine sediment (\>3 red blood cells per high-power field or red blood cell casts)

2.2. Statistical Analysis {#sec2.2}
-------------------------

Normally distributed variables were expressed as mean ± standard deviation (SD) and compared using independent samples *t*-test or one-way ANOVA. Nonparametric variables were expressed as medians and interquartile range (IQR) and compared using Mann--Whitney *U* or Kruskal--Wallis test. Categorical variables were compared using a *χ*2-test. To examine correlations between risk factors and renal involvement, univariate analyses were used, firstly based on biological plausibility and literature review. Variables with *P* \< 0.05 in univariate analysis were then included in a multivariate analysis using logistic regression. Statistical significance was set at *P* \< 0.05. All analyses were conducted using SPSS 22.0 statistical software packages. Receiver operating characteristic (ROC) curves were plotted to explore the significance of multiple biomarkers for renal function in pSS. The differences among the areas under the receiver operating characteristic (ROC) curves (AUC) were calculated by MedCalc Software (version 15.2.0; MedCalc Software, Belgium).

3. Results {#sec3}
==========

3.1. The Characteristics of pSS Patients with or without Renal Involvement {#sec3.1}
--------------------------------------------------------------------------

Demographic, clinical, histological, immunological, inflammatory feature, and outcome measure data were presented in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}, collected from -162 pSS patients with and 840 without renal involvement. The female to male ratio in pSS patients is 779 : 61 (92.7%). Most patients presented to the hospital at 49 years old for the first interview, and an average disease course was approximately 5 years. Compared with pSS patients without renal involvement, those with renal involvement showed much higher levels of prealbumin, anti-scl-70, rheumatoid factor (RF), anti-extractable nuclear antigen (anti-ENA), anti-SSA, anti-SSB, anti-SM, globulin, urea nitrogen, cystatin C, creatinine, *α*~1~-MG, serum *β*2 microglobulin (*β*~2~-MG), uric acid, Cl, lipoprotein-a, acid phosphatase, ESR, parathyroid hormone (PTH), and carcinoembryonic antigen (CEA), but reduced level of monocyte, anti-SSA, total protein, albumin, carbon dioxide combining power (CO2CP), Ca, red blood cell (RBC), hemoglobin (Hb), apolipoprotein-A~1~, immunoglobulin M (IgM), and complement-C3 (*P* \< 0.05). Comparison of the two groups of clinical manifestations is shown in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}.

3.2. The Characteristics of Renal Involvement in Primary Sjogren\'s Syndrome Patients {#sec3.2}
-------------------------------------------------------------------------------------

The SS patients with renal involvements showed glandular symptoms (xerostomia and xerophthalmia) and extraglandular symptoms (arthritis, erythema, edema, and digestive, respiratory, and renal involvement). Pathological features of patients with pSS with renal involvement are shown in [Table 3](#tab3){ref-type="table"}. In the 12 biopsy patients with pSS with renal involvement, 6 cases had interstitial nephritis and 3 cases had mesangial glomerulonephritis. Three cases had membranous glomerulonephritis, one case diabetic nephropathy, and one case IgA nephropathy.

And the renal damage is shown in [Table 4](#tab4){ref-type="table"}. The prevalence of edema of both lower limbs was higher than 20%. Meanwhile, the occurrences of hypourocrinia, frequent micturition, urgency of urine, hematuria, and diuresis were comparatively low.

3.3. Specific Factors Associated with Renal Involvement in pSS Patients {#sec3.3}
-----------------------------------------------------------------------

A series of indicators commonly used in clinical practice were selected first by univariate analysis and then logistic regression analysis as potential risk factors for renal involvement in pSS. As is shown in Tables [4](#tab4){ref-type="table"} and [5](#tab5){ref-type="table"}, a series of variables were found to be associated with renal involvement. Compared with pSS patients without renal involvement, edema of both lower limbs and digestive tract involvement were important clinical manifestations (*P* \< 0.05).

There was a statistical significance in creatinine, cystatin C, *α*~1~-MG, and chloridion between pSS patients with and without renal damage.

3.4. Comparison of ROC Curves and AUC of Creatinine, Cystatin C, and *α*~1~-MG {#sec3.4}
------------------------------------------------------------------------------

To compare the significance of multiple indicators (creatinine, cystatin C, and *α*~1~-MG) that had significant differences between the two groups in the identification of renal function, we have plotted ROC curves for these biomarkers ([Figure 1](#fig1){ref-type="fig"}). For the renal function biomarkers, there was no significant difference in the AUC for biomarkers (cystatin C, index: 0.728, CI 0.699-0.755; *α*~1~-MG: 0.775, CI 0.748-0.801; and cystatin C+creatinine: 0.794, CI 0.748-0.801) compared with creatinine. The AUC of combination of creatinine+*α*~1~-MG and creatinine+*α*~1~-MG+creatinine were statistically larger than those of creatinine, and the biomarker of the biggest AUC is the combination of creatinine+*α*~1~-MG ([Table 6](#tab6){ref-type="table"}).

4. Discussion {#sec4}
=============

There were 162 patients with renal involvement in this study, and the incidence rate was 16.17% (162/1002). In Goules\'s study, the prevalence of renal involvement was identified as 4.9% \[[@B6]\]. Another Chinese study also reported a relatively high incidence (33%) of renal abnormalities (based on biochemical abnormalities or kidney biopsy findings) in a study of 524 patients with PSS, 33% \[[@B7]\]. Because of a large number of study subjects in this work, our results suggest that the number of patients and geographical and ethnic factors might contribute to such variability.

PSS is characterized by B-cell activation with high serum IgG levels and a high frequency of autoantibodies \[[@B8]\]. In our study, pSS patients had multiple autoantibodies such as anti-SSA, anti-SSB, and ANA antibody, suggesting that pSS with renal abnormalities may be related to immune dysfunction. However, the pathological features of pSS with renal damage are the lymphocytic infiltration of the renal parenchyma rather than immune complex deposition and renal tubular atrophy that mainly presented interstitial nephritis mediated by an immune mechanism \[[@B9]--[@B11]\]. Although investigations about treatments targeting the immune factors participating in the progression of pSS show some positive outcome, more clinical trials were required before their application in human \[[@B12]\].

Among various manifestations of renal involvement, glomerular arterioles may be pathologically changed to glomerulonephritis, and a previous study showed that tubulointerstitial nephritis (TIN) is the most common presentation of renal involvement in the biopsy of pSS, which is consistent with our study \[[@B13]\].

Creatinine is primarily eliminated by glomerular filtration, and it can be used as a convenient means for estimating the glomerular filtration rate. Therefore, measurement of serum creatinine levels is the most common method used clinically for the routine monitoring of renal function \[[@B14]\]. Several studies have shown that serum cystatin C levels were more sensitive for detecting early and mild changes in renal function compared with the sensitivity of serum creatinine levels \[[@B15]\]. Serum cystatin C was produced at a constant rate by all nucleated body cells and was independent of age and gender \[[@B16]--[@B18]\]. Cystatin C was freely filtered at the glomerulus and was neither secreted nor reabsorbed by renal tubules \[[@B19]\]. Cystatin can reflect the decline of glomerular filtration rate that was the most direct indicator of renal damage, and it can be used as markers for early renal damage \[[@B20], [@B21]\]. In our study, the level of cystatin C showed a significant difference between patients with and without renal involvement and was identified as a potential risk factor for renal involvement, which was consistent with another study.

*α* ~1~-MG was described and isolated from the urine of patients with chronic cadmium poisoning in 1975 \[[@B22]\]. The biochemical characteristics and clinical application value of alpha-1-microglobulin have been studied by scholars. It is synthesized not only by lymphocytes in the human body \[[@B2]\] but also by the liver \[[@B23]\], and it widely exists in various body fluids and on the surface of lymphocytes. *α*~1~-MG also is a stable urinary indicator protein which reflects acute and chronic dysfunctions of the proximal renal tubule. Our laboratory examination showed that the level of alpha-1-microglobulin in the pSS with renal damage group was significantly higher than that in the nonrenal damage group, which indicated the damage of proximal renal tubule and subsequent immune response to lymphocyte infiltration of the renal parenchyma in pSS. The combination of creatinine and *α*~1~-MG had the best AUC, indicating that the combination of creatinine and *α*~1~-MG was more effective in identifying renal function in pSS.

However, limitations of this study should be indicated. Firstly, the limited sample size, as well as bias caused by single-center analysis, should be considered, and secondly, as a cross-sectional study, it is limited to correlation analysis and unable to support strong causal conclusions. Therefore, to further evaluate the role of complement renal complications in SS, more data from heterogeneous SS patients with consecutive follow-up are highly recommended.

5. Conclusions {#sec5}
==============

Renal involvement is common in pSS patients. The combination of creatinine and *α*~1~-MG is a better indicator of renal function for pSS patients, and close attention should be paid to it in clinical practice.
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###### 

Demographic, clinical, histological, immunological, and inflammatory features of primary Sjogren\'s syndrome with or without renal involvement.

  ------------------------------------------------------------------------------------------------
                                Without renal involvement\   With renal involvement\   *P* value
                                840                          162                       
  ----------------------------- ---------------------------- ------------------------- -----------
  Seroperitoneum                0                            6 (3.7%)                  0.000

  Dizziness                     12 (1.4%)                    8 (4.9%)                  0.003

  Palpitate                     14 (1.7%)                    6 (3.7%)                  0.090

  Breathe hard                  26 (3.1%)                    9 (5.6%)                  0.118

  Digestive tract symptoms      19 (2.3%)                    31 (19.1%)                0.000

  Respiratory system symptoms   30 (3.6%)                    15 (9.3%)                 0.001

  Congestion of throat          1 (0.1%)                     10 (6.2%)                 0.000

  Bilateral pleural effusion    0                            3 (1.9%)                  0.000

  Lipsotrichia                  53 (6.3%)                    4 (2.5%)                  0.053

  Dry cough                     4 (0.5%)                     1 (0.6%)                  0.815

  Edema in the face             5 (0.6%)                     14 (8.6%)                 0.000

  Edema of both lower limbs     13 (1.5%)                    42 (25.9%)                0.000

  Hypourocrinia                 0                            4 (2.5%)                  0.000

  Frequent micturition          8 (1.0%)                     10 (6.2%)                 0.000

  Urgency of urine              8 (1.0%)                     7 (4.3%)                  0.000

  Odynuria                      3 (0.4%)                     4 (2.5%)                  0.003

  Rampant caries                187 (22.3%)                  34 (21%)                  0.720

  Erythema                      149 (17.7%)                  23 (14.2%)                0.274

  Weak                          119 (14.2%)                  50 (30.9%)                0.000

  Poor appetite                 9 (1.0%)                     25 (15.4%)                0.000

  Dry mouth                     669 (79.6%)                  129 (79.6%)               0.997

  Xerophthalmia                 457 (54.4%)                  94 (58%)                  0.396

  Arthralgia                    493 (58.7%)                  68 (42%)                  0.000

  Fever                         149 (17.7%)                  28 (17.3%)                0.890

  Reynolds                      33 (3.9%)                    9 (5.6%)                  0.344

  Dental ulcer                  69 (8.2%)                    16 (9.9%)                 0.487

  Courpature                    1 (0.1%)                     1 (0.6%)                  0.193

  Hematuria                     0                            1 (0.6%)                  0.023

  Polydipsia                    1 (0.1%)                     2 (1.2%)                  0.021

  Diuresis                      1 (0.1%)                     2 (1.2%)                  0.021

  Nocturia                      2 (0.2%)                     17 (18.5%)                0.000

  Parotid swelling and pain     29 (3.5%)                    3 (1.9%)                  0.289

  Anti-scl-70                   0                            2 (1.2%)                  0.001

  Anti-Jo-1                     0                            2 (1.2%)                  0.001

  pANCA                         17 (2%)                      4 (2.5%)                  0.717

  cANCA                         3 (0.4%)                     1 (0.6%)                  0.631

  RF                            144 (17.1%)                  44 (27.2%)                0.003

  Anti-ENA                      169 (20.1%)                  59 (36.4%)                0.000

  Anti-ds DNA                   18 (2.1%)                    3 (1.9%)                  0.813

  Anti-SSA                      579 (68.9%)                  80 (49.4%)                0.000

  Anti-SSB                      54 (6.4%)                    19 (11.7%)                0.017

  Anti-Sm                       4 (0.5%)                     4 (2.5%)                  0.009

  Anti-RNP                      87 (10.4%)                   15 (9.3%)                 0.672
  ------------------------------------------------------------------------------------------------

###### 

Demographic, clinical, histological, immunological and inflammatory features of primary Sjogren\'s syndrome with or without renal involvement.

  -----------------------------------------------------------------------------------------------------------------
                                                 Without renal involvement\   With renal involvement\   *P* value
                                                 840                          162                       
  ---------------------------------------------- ---------------------------- ------------------------- -----------
  Age                                            49.46 ± 13.36                49.94 ± 15.39             0.713

  Mouth disease                                  69.44 ± 83.05                56.76 ± 91.78             0.082

  White blood cell                               6.15 ± 3.035                 6.34 ± 3.03               0.485

  RBC                                            4.08 ± 0.61                  3.66 ± 0.87               0.000

  Hb                                             122.61 ± 26.56               109.75 ± 24.94            0.000

  Platelet                                       209.61 ± 101.51              214.66 ± 100.74           0.562

  Monocyte                                       0.43 ± 0.25                  0.45 ± 0.42               0.402

  Eosinophil                                     0.11 ± 0.17                  0.13 ± 0.16               0.181

  Lymphocyte%                                    28.73 ± 11.31                28.57 ± 11.82             0.872

  Lymphocyte                                     1.66 ± 1.64                  1.66 ± 0.84               0.973

  Monocyte%                                      7.44 ± 3.85                  6.77 ± 2.49               0.005

  Eosinophil%                                    1.86 ± 2.35                  1.97 ± 2.15               0.568

  Urine RBC                                      5.79 ± 38.71                 26.95 ± 100.88            0.009

  Urine WBC                                      18.30 ± 57.64                11.60 ± 39.55             0.071

  Urine pH                                       6.34 ± 0.78                  6.28 ± 1.00               0.463

  Proportion                                     1.02 ± 0.01                  1.02 ± 0.01               0.074

  ALT                                            32.81 ± 35.05                30.9 ± 77.11              0.618

  AST                                            32.66 ± 33.19                35.79 ± 80.43             0.626

  AST/ALT                                        1.18 ± 0.56                  1.28 ± 0.47               0.039

  Total bilirubin                                14.26 ± 14.24                13.04 ± 33.11             0.445

  Direct bilirubin                               4.19 ± 7.15                  4.53 ± 19.00              0.822

  Indirect bilirubin                             10.06 ± 8.34                 8.77 ± 14.62              0.121

  Prealbumin                                     234.65 ± 56.94               262.90 ± 66.57            0.000

  Total protein                                  71.10 ± 10.40                68.16 ± 11.80             0.000

  Albumin                                        37.28 ± 5.51                 34.475 ± 6.87             0.004

  Globulin                                       33.45 ± 9.10                 33.70 ± 9.48              0.000

  Albumin/globulin                               1.19 ± 0.35                  1.10 ± 0.36               0.001

  Alkaline phosphatase                           99.26 ± 99.52                102.35 ± 68.45            0.687

  Glutamyl transpeptidase                        53.52 ± 102.20               37.64 ± 69.78             0.015

  Total bile acid                                9.73 ± 20.71                 10.21 ± 37.32             0.815

  5-Nucleoglykase                                8.45 ± 14.37                 6.73 ± 10.15              0.147

  Adenosine deaminase                            19.01 ± 11.93                18.84 ± 9.07              0.858

  Blood glucose (4.2-6.1)                        5.31 ± 1.57                  5.18 ± 1.06               0.332

  Fructosamine                                   1.83 ± 0.65                  1.81 ± 0.56               0.633

  Urea nitrogen                                  4.50 ± 1.76                  8.43 ± 6.62               0.000

  Creatinine                                     55.70 ± 14.32                150.82 ± 150.41           0.000

  CO~2~ CP                                       25.08 ± 2.84                 22.54 ± 4.60              0.000

  Cystatin C                                     1.09 ± 0.36                  2.04 ± 1.38               0.000

  *α* ~1~-MG (10-30 ng/L)                        20.89 ± 7.95                 34.04 ± 15.93             0.000

  *β* ~2~-MG (0.97-2.64 ng/L)                    2.81 ± 5.19                  6.02 ± 5.64               0.000

  Uric acid (90-420 *μ*mol/L)                    246.66 ± 78.60               292.70 ± 115.11           0.000

  Complement-C1q (159-233 mg/L)                  198.06 ± 14.16               199.79 ± 15.72            0.164

  K (3.5-5.5 mmol/L)                             3.91 ± 0.41                  3.93 ± 0.63               0.631

  Na (137-147 mmol/L)                            139.50 ± 3.47                139.31 ± 4.08             0.579

  Cl (99-110 mmol/L)                             105.34 ± 3.66                107.38 ± 5.36             0.000

  Ca (2.08-2.6 mmol/L)                           2.24 ± 0.14                  2.19 ± 0.18               0.000

  P (0.83-1.48 mmol/L)                           1.23 ± 0.50                  1.26 ± 0.30               0.465

  Mg (0.7-1.1 mmol/L)                            0.91 ± 0.10                  0.93 ± 0.12               0.145

  Fe                                             14.07 ± 6.61                 13.31 ± 7.20              0.190

  CK                                             66.41 ± 124.01               82.60 ± 192.51            0.304

  CK-MB                                          9.39 ± 8.96                  8.90 ± 6.54               0.502

  LDH                                            221.41 ± 168.21              233.16 ± 201.45           0.432

  HBD                                            173.22 ± 141.13              180.03 ± 136.94           0.572

  Total cholesterol                              4.55 ± 1.25                  4.53 ± 1.82               0.883

  Triglyceride                                   1.90 ± 2.05                  2.18 ± 2.36               0.156

  HDL                                            1.21 ± 0.43                  1.14 ± 0.37               0.054

  LDL                                            2.66 ± 0.84                  2.61 ± 1.25               0.607

  Apolipoprotein-A~1~                            1.30 ± 0.39                  1.23 ± 0.32               0.033

  Apolipoprotein-B100                            0.84 ± 0.23                  0.90 ± 0.38               0.581

  Apolipoprotein-E                               38.84 ± 12.74                40.23 ± 22.27             0.443

  Lipoprotein-*α*                                18.41 ± 18.30                23.19 ± 21.88             0.010

  HDL/cholesterol                                27.13 ± 7.68                 21.51 ± 9.02              0.615

  Acid phosphatase                               4.29 ± 2.76                  5.15 ± 2.82               0.000

  ESR                                            38.29 ± 33.68                54.84 ± 36.36             0.000

  CRP                                            10.35 ± 20.25                10.62 ± 20.50             0.877

  Complement-C3                                  1.01 ± 0.24                  0.95 ± 0.22               0.004

  Complement-C4                                  0.23 ± 0.25                  0.25 ± 0.14               0.370

  PTH                                            38.52 ± 17.82                220.28 ± 307.65           0.032

  CA19-9 (\<35 KU/L)                             12.45 ± 16.20                13.12 ± 15.81             0.624

  CEA \< 5 ng/L                                  2.17 ± 1.55                  2.33 ± 0.99               0.021

  AFP \< 20 ng/L                                 2.81 ± 2.06                  2.73 ± 2.36               0.655

  IgG                                            14.84 ± 6.78                 14.76 ± 7.59              0.891

  IgA                                            2.86 ± 1.46                  3.02 ± 1.31               0.192

  IgM                                            1.64 ± 1.39                  1.37 ± 0.75               0.000

  Light chain quantitative *κ* (5.74-12.8 g/L)   7.87 ± 26.02                 11.96± 8.27               0.283

  Light chain quantitative L (2.69-6.38 g/L)     2.08 ± 3.87                  86.07 ± 565.90            0.294
  -----------------------------------------------------------------------------------------------------------------

###### 

Pathological types of kidney in 12 PSS patients with renal involvement.

  Pathological type                                                                     Case
  ------------------------------------------------------------------------------------- ------
  Mild mesangial proliferative nephritis with subacute tubulointerstitial nephropathy   1
  Stage III glomerulosclerosis of nodular sclerosing diabetes mellitus                  1
  Mild mesangial hyperplasia                                                            1
  Atypical membranous nephropathy                                                       1
  Changes of renal tubular injury during convalescence                                  1
  Focal proliferative sclerosing glomerulonephritis                                     1
  Focal proliferative IgA nephropathy                                                   1
  Subacute tubulointerstitial nephropathy                                               1
  Mild mesangial proliferative nephritis with subacute tubulointerstitial nephropathy   1
  Stages I-II membranous nephropathy                                                    1
  Chronic interstitial renal damage                                                     1
  Atypical membranous nephropathy with multiple crescents and acute tubular injury      1

###### 

Features of renal involvement in primary Sjogren\'s syndrome patients.

  Renal involvement           Numbers   Percentage (%)
  --------------------------- --------- ----------------
  Edema in the face           14        8.6
  Edema of both lower limbs   42        25.9
  Hypourocrinia               4         2.5
  Frequent micturition        10        6.2
  Urgency of urine            7         4.3
  Hematuria                   1         0.6
  Diuresis                    2         1.2
  Nocturia                    17        18.5
  Interstitial nephritis      6         3.7
  Renal tubular acidosis      12        7.4

###### 

Multivariate analysis of factors associated with renal involvement in primary Sjogren\'s syndrome.

  Independent variables             Muitivariate analysis OR (95% Cl)   *P* value
  --------------------------------- ----------------------------------- -----------
  Arthralgia                        1.32 (0.79, 2.22)                   0.294
  Weak                              1.83 (1.01, 3.31)                   0.046
  Poor appetite                     1.52 (0.34, 6.74)                   0.580
  Edema in the face                 3.33 (0.58, 19.25)                  0.179
  Edema of both lower limbs         9.16 (3.18, 26.39)                  0.000
  Hypourocrinia                     3768741.41 (0.00)                   0.999
  Frequent micturition              2.30 (0.03, 197.13)                 0.714
  Urgency of urine                  0.51 (0.01, 27.65)                  0.740
  Odynuria                          1.46 (0.02, 87.33)                  0.856
  Hematuria                         97021762.92 (0.00)                  1.000
  Polydipsia                        2521.28 (0.00)                      0.999
  Diuresis                          0.00 (0.00)                         0.999
  Digestive tract symptoms          3.06 (1.02, 9.22)                   0.047
  Respiratory system symptoms       0.83 (0.23, 3.01)                   0.779
  Congestion of throat              9.02 (0.16, 507.78)                 0.285
  Bilateral pleural effusion        16009499.05 (0.00)                  0.999
  RBC (3.5-5.5 × 10^12^/L)          1.12 (0.70, 1.81)                   0.637
  Hb (110-150 g/L)                  1.00 (0.99, 1.01)                   0.831
  Urine RBC                         1.01 (1.00, 1.01)                   0.015
  AST/ALT                           1.00 (0.68, 1.49)                   0.987
  Prealbumin                        1.01 (1.00, 1.01)                   0.026
  Total protein (65-85 g/L)         0.99 (0.95, 1.04)                   0.778
  A/G                               1.37 (0.28, 6.68)                   0.699
  Creatinine (44-133 *μ*mol/L)      1.03 (1.01, 1.04)                   0.000
  Urea nitrogen (2.8-68.2 mmol/L)   0.97 (0.85, 1.10)                   0.628
  CO~2~ CP (22-29 mmol/L)           0.95 (0.87, 1.03)                   0.220
  Cystatin C (0.1-0.3 mmol/L)       1.83 (1.16, 2.87)                   0.009
  *α* ~1~-MG (10-30 mg/L)           1.03 (1.00, 1.05)                   0.021
  Uric acid (90-420 *μ*mol/L)       1.00 (1.00, 1.00)                   0.323
  *β* ~2~-MG (0.97-2.64 mg/L)       1.01 (0.96, 1.06)                   0.805
  Cl (99-110 mmol/L)                1.10 (1.03, 1.12)                   0.004
  Ca (2.08-2.6 mmol/L)              3.49 (0.47, 25.83)                  0.221
  Apolipoprotein A~1~               0.56 (0.26, 1.20)                   0.134
  Lipoprotein-*α*                   1.00 (0.99, 1.02)                   0.508
  Acid phosphatase (1-9 U/L)        1.00 (0.91, 1.09)                   0.916
  ESR                               1.01 (1.00, 1.02)                   0.126
  Complement-C3 (30.8-82.01 g/L)    0.46 (0.15, 1.37)                   0.161
  IgM                               0.91 (0.71, 1.16)                   0.434

###### 

AUC of creatinine, cystatin C, and *α*~1~-MG.

                                               AUC     95% CI        *P* value
  -------------------------------------------- ------- ------------- -------------------------
  Creatinine                                   0.777   0.750-0.803   
  Cystatin C                                   0.728   0.699-0.755   \>0.05 (vs. creatinine)
  *α*1-Microglobulin                           0.775   0.748-0.801   \>0.05 (vs. creatinine)
  Creatinine+cystatin C                        0.794   0.767-0.819   \>0.05 (vs. creatinine)
  Creatinine+*α*1-microglobulin                0.824   0.799-0.847   \<0.05 (vs. creatinine)
  Creatinine+cystatin C + *α*1-microglobulin   0.819   0.794-0.843   \<0.05 (vs. creatinine)

AUC: area under the curve; CI: confidence interval.

[^1]: Guest Editor: Long Shen
